Imperative Care Announces 10,000 Patients Treated With Its Innovative Stroke Technologies
Company Reaches Milestone During Stroke Awareness Month, Serving as a Reminder to Learn the Signs of Stroke May 25, 2022
Pioneering Medical Innovations
Pioneering Medical Innovations
Company Reaches Milestone During Stroke Awareness Month, Serving as a Reminder to Learn the Signs of Stroke May 25, 2022
First regulatory milestone as part of a strategy to advance patient care April 11, 2022 08:00 AM Eastern Daylight Time
Prospective study will evaluate safety and efficacy of the Zoom 88 Large Distal Platform for aspiration within eight hours of
Significant milestone in company’s mission to advance stroke care CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a company singularly dedicated to answering
Company Founded with Mission to Give Stroke Patients the Best Chance for Optimal Recovery CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a
June 5, 2017—The FDA has cleared the use of Claret Medical’s Sentinel cerebral protection system in the U.S., making the device the first and only of its kind on the market that reduces the risk of stroke by capturing and removing debris that can break free during transcatheter aortic valve replacement (TAVR) and cause a stroke, the company said.
June 5, 2017—The First and Only Embolic Protection Device Shown to Reduce TAVR Procedural Strokes by 63 Percent
Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency BEDFORD, Mass.–(BUSINESS WIRE)–Augmenix, Inc.,
February 27, 2017—Claret Medical Inc. announced that in an open public hearing of the US Food and Drug Administration’s Circulatory System Devices Panel held on February 23, virtually all panel members recommended the de novo application of the company’s Sentinel cerebral protection system (CPS) be granted, which would enable commercialization of the device in the United States. A formal vote was not taken, as the Sentinel CPS is a medium-risk accessory device reviewed as a de novo application, advised the company.
Despite the cloud of questions surrounding its clinical efficacy, an FDA advisory panel overwhelmingly recommended approval for the Sentinel Cerebral Protection System. As a de novo application for a lower-risk device, the Sentinel did not require a formal panel vote.